Close Menu

Out in the Light

During the first six months of 2009, Pfizer paid about $20 million to some 4,500 medical professionals in consulting and speaking fees, reports the New York Times. In addition, Pfizer paid $15.3 million to 250 academic medical centers for clinical trials. These details were released as part of an agreement Pfizer made with the US government during an investigation into the company's promotion of drugs for off-label uses. Eli Lilly, Merck, and GlaxoSmithKline have made similar disclosures.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.